In a nutshell This study investigated the safety and effectiveness of treatment with combination cyclophosphamide (Cytoxan), methotrexate (Otrexup) and 5-fluoruoracil (Efudex) (CMF) plus trastuzumab (Herceptin) in HER2-positive metastatic breast cancer (MBC, cancer that has spread beyond the breast) patients. CMF plus trastuzumab (CMF+T) was found to...
Read MoreBreast cancer Posts on Medivizor
Does radiotherapy benefit older patients with triple-negative breast cancer
In a nutshell This study investigated the effects of radiotherapy (RT) in older patients with triple-negative breast cancer (TNBC). RT was found to be associated with better survival outcomes for both younger and older patients. Some background TNBC is a form of breast cancer which tests negative for estrogen/ progesterone receptors and human...
Read MoreHow effective is metronomic chemotherapy with vinorelbine and capecitabine in patients with advanced HER2-negative breast cancer?
In a nutshell This study investigated whether metronomic chemotherapy with oral vinorelbine (Navelbine) and capecitabine (Xeloda) was effective in treating patients with advanced HER2-negative breast cancer (BC). This form of treatment was found to be safe and effective for this patients group. Some background Metronomic chemotherapy is a form of...
Read MoreComparing the effects of combined PI3K inhibitor/endocrine therapy versus endocrine therapy alone in ER-positive breast cancer
In a nutshell This study investigated whether the addition of the PI3K inhibitor pictilisib (Stemolecule GDC-0941) can increase the anti-tumor effects of anastrozole (Arimidex) in patients with estrogen receptor-positive (ER-positive) primary breast cancer (BC). Combined treatment with pictilisib (PIC)...
Read MoreThe beneficial effects of trastuzumab on locoregional control in HER2-positive breast cancer patients.
In a nutshell This study investigated the effects of trastuzumab (Herceptin) on the locoregional control (management in the area in which it arose) of patients with HER2-positive breast cancer (HER2+BC) following radiotherapy (RT). Trastuzumab administered alongside RT was found to be associated with a significantly reduced rate of locoregional...
Read MoreThe impact of exercise on the risk of cardiovascular events in women with non-metastatic breast cancer
In a nutshell This study investigated whether exercise was associated with a reduction in the risk of cardiovascular disease (CVD) in patients with non-metastatic breast cancer (BC). Exercise was found to be linked to a significant reduction in the risk of CVD for this patient group. Some background CVD is a leading cause of death among women with...
Read MoreHow does hormone receptor status affect patient response to trastuzumab therapy in metastatic breast cancer
In a nutshell This study investigated the clinical factors that influence patient response to trastuzumab (Herceptin) therapy in human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC). Hormone receptor (HR) status was found to be a possible predictor of a strong response to trastuzumab-based therapy. Some background...
Read MorePatients’ Voice In Research: First Results From The Metastatic Breast Cancer Project
In July 2015, Medivizor introduced us to a project being conducted by the Broad Institute in conjunction with Dana Farber Cancer Institute called The Metastatic Breast Cancer Project or MBC Project. In October of 2015, after two years of work involving patient input and partnership, the MBC Project website went live. One of the reasons why this project is...
Read MoreIncidence of ovarian function recovery in women over 40 with chemotherapy induced amenorrhea
In a nutshell This study investigated ovarian function recovery (OFR) after chemotherapy-induced amenorrhea (absence of menstruation) in women aged 40-49 after 2 years of aromatase inhibitor (AI) therapy. The study concluded that a large number of women with chemotherapy-induced amenorrhea recover ovarian function during AI therapy. Some...
Read MoreTen years on: Axillary recurrence after negative sentinel node biopsy for breast cancer
In a nutshell This study investigated the long term risk of axillary (underarm lymph node) recurrence in breast cancer (BC) patients who were not treated with axillary lymph node dissection (ALND) following a negative sentinel node biopsy (SNB) result. The study concluded that the risk of axillary recurrence after 10 years was lower than expected after...
Read MoreUpdated guidelines for using radiotherapy after breast removal in breast cancer patients
In a nutshell This study reviewed updated guidelines for the use of radiotherapy following mastectomy (surgical removal of the breast) in breast cancer. Some background Post-mastectomy radiation therapy (PMRT) is widely accepted for patients with four or more involved axillary (underarm) lymph nodes. The axillary lymph nodes are the first...
Read MoreComparing axillary lymph node ultrasound and fine needle aspiration in breast cancer
In a nutshell This study investigated whether patients with a suspicious axillary lymph node (ALN) but negative fine-needle aspiration result (FNA) can be considered as having node-negative disease (AUN). The study concluded that patients with suspicious ALN on ultrasound but negative FNA results can be treated as having node-negative disease. Some...
Read More
